Crisis in CEE pharma innovative market
Innovative pharmaceutical companies face a crisis associated with the loss of patent rights pertaining to their most important products, and this includes in the central and eastern Europe region, according to local market consultancy PMR.
Between 2008 and 2012, the research-based drugmakers most endangered by the risk of generic competition in the CEE region, it says, will be: UK drug giant GlaxoSmithKline; US majors Pfizer and Bristol Myers-Squibb; Japan's Astellas Pharma; and Anglo-Swedish AstraZeneca.
Acquiring generics makers could be answer
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze